Avalyn Pharma Inc. Common Stock
NASDAQ:AVLNMedical - Pharmaceuticals
+$0.52 today
- Market cap
- $1.23B
- Beta
- 0.00
Volume 0.40M
Average 0.51M
AVLN Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Capital Expenditures history
Currency unavailable · from the cash flow
No Capital Expenditures data reported for this period type.
Capital Expenditures vs competitors
How AVLN compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $58.75M USD | +144.6% | +48.8% | 5.2% | |
| LTM Mar 2026 | $6.12M USD | -19.7% | -15.6% | 1.7% | |
| LTM Mar 2026 | $1.28M USD | -65.4% | -38.0% | 1.1% | |
VCREVicore Pharma Holding AB | LTM Jun 2026 | SEK 0 SEK | — | — | 0.0% |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding AVLN) | — | -19.7% | -15.6% | 1.4% | |
Competitors are the stored peer set for AVLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Avalyn Pharma Inc. Common Stock
NASDAQ:AVLN
Intrinsic Alpha fair value
Locked
Current Price
$27.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.